Grand Promenade

Grand Ming Group Holdings Limited Announces Interim Results for the Six Months Ended 30 September 2022

Retrieved on: 
Saturday, November 12, 2022

HONG KONG, Nov 12, 2022 - (ACN Newswire) - Grand Ming Group Holdings Limited (the "Company" and together with its subsidiaries, the "Group", stock code: 1271.HK) today announces its interim results for the six months ended 30 September 2022 ("FH 2022/23").

Key Points: 
  • HONG KONG, Nov 12, 2022 - (ACN Newswire) - Grand Ming Group Holdings Limited (the "Company" and together with its subsidiaries, the "Group", stock code: 1271.HK) today announces its interim results for the six months ended 30 September 2022 ("FH 2022/23").
  • The Group's consolidated revenue increased by 7.4 times from HK$586.1 million for the six months ended 30 September 2021 ("FH 2021/22") to HK$4,920.1 million for FH 2022/23.
  • Handover of the pre-sold units to buyers subsequently commenced in April 2022, with revenue of HK$4.77 billion recognised during FH 2022/23.
  • About Grand Ming Group Holdings Limited (Stock code: 1271.HK)
    The Group is principally engaged in the business of building construction, property leasing and property development.

Novan Announces Presentation of Two Posters at the 2022 Winter Clinical Dermatology Conference

Retrieved on: 
Friday, January 14, 2022

DURHAM, N.C., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (the Company or Novan) (Nasdaq: NOVN), today announced that data from the Companys completed Phase 2 and Phase 3 clinical studies of berdazimer 10.3% gel (previously referred to as SB206) for molluscum contagiosum will be presented at the 2022 Winter Clinical Dermatology Conference, being held January 14-19, 2022, in Koloa, Hawaii.

Key Points: 
  • DURHAM, N.C., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (the Company or Novan) (Nasdaq: NOVN), today announced that data from the Companys completed Phase 2 and Phase 3 clinical studies of berdazimer 10.3% gel (previously referred to as SB206) for molluscum contagiosum will be presented at the 2022 Winter Clinical Dermatology Conference, being held January 14-19, 2022, in Koloa, Hawaii.
  • There is currently no US Food & Drug Administration (FDA) approved medication indicated for the treatment of molluscum.
  • The latter represents a clinical sign of inflammation and imminent resolution of molluscum lesions that has never been prospectively studied in a molluscum clinical trial.
  • For more information about the conference, visit: https://fallclinical.health/
    Novan, Inc. is a pre-commercial nitric oxide-based pharmaceutical company focused on dermatology and anti-infective therapies.

Dermavant to Present New Data from Phase 3 PSOARING Program at the 2022 Winter Clinical Dermatology Conference

Retrieved on: 
Friday, January 7, 2022

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date in Q2 2022.

Key Points: 
  • The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date in Q2 2022.
  • Dermavants pivotal Phase 3 clinical program for tapinarof in adult plaque psoriasis consists of PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980), as well as PSOARING 3 (NCT04053387), a long-term extension study.
  • Greater than 90% of eligible patients who completed PSOARING 1 and PSOARING 2 enrolled in PSOARING 3.
  • For more information, please visit www.dermavant.com , and follow us on Twitter ( @dermavant ) and LinkedIn ( Dermavant Sciences ).